Global Furosemide Injections Market Size, Share, and Trends Analysis Report, By Application (Congestive Heart Failures, Liver Diseases, and Kidney Diseases) and By Distribution Channel (Hospital Pharmacies, and Retail Drug Stores), Forecast (2022-2028)

The global furosemide injections market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Furosemide injection is a diuretic medication used to treat fluid retention and swelling caused due to liver diseases, congestive heart failures, and kidney diseases by increasing the amount of urine in the body. The major factor attributing to the growth of the global furosemide injections market includes the rising prevalence of kidney diseases across the globe. According to the Centers for Disease Control and Prevention (CDC), around 37 million adults have chronic kidney disease in the US alone with most of them undiagnosed. Around 360 people begin their dialysis treatment for kidney failure every 24 hours and around 40% of people with severely reduced kidney function are unaware of the condition making kidney disease one of the leading causes of mortality in the US.

 

 

In addition, the application of furosemide injections is also increasing in the treatment of swelling due to congestive heart failure. According to the Heart Failure Society of America (HFSA), around 5.5 million new cases of congestive heart failure are diagnosed every year in the US with around 5 million people living with congestive heart failure in the US. Congestive heart failure can affect people of all ages, including children, adults, and elders. Around 1.4 million people with congestive heart failure are under the age of 60 years and after 60 years of age, the prevalence of congestive heart failure is around 10 in every 1,000 people in the US.

 

 

The increasing application of furosemide injections in the treatment of patients with liver diseases is also supporting the growth of the market. According to the CDC, around 4.5 million adults are diagnosed with liver diseases in the US representing 1.8% of the adult population. Around 51,642 mortalities were caused due to this disease in the US in 2019. Thus, boosting the demand for furosemide injections.

 

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- SteriMax Inc., Baxter International Inc., Pfizer Inc., AuroMedics Inc., and Teva Pharmaceuticals Industries Ltd., among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Furosemide Injections  Market Report by Segment

By Application

• Congestive Heart Failures
• Liver Diseases
• Kidney Diseases

By Distribution Channel

• Hospital Pharmacies
• Retail Drug Stores

Global Furosemide Injections  Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa